Previous 10 | Next 10 |
2023-12-30 06:50:00 ET Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be monster winners in 2024. H...
2023-12-29 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-18 02:54:02 ET Summary Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their main candidate drug, ensifentrine, has shown promising results in clinical trials for COPD, cystic fibrosis, a...
LONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognitio...
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023: Jefferies London Hea...
Verona Pharma plc (VRNA) is expected to report $-0.27 for Q3 2023
2023-11-04 11:58:02 ET Verona Pharma plc (VRNA) Q3 2023 Results Conference Call November 02, 2023 09:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer Chris Martin - SVP, Commercial Confe...
2023-11-02 03:22:42 ET More on Verona Pharma Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon Verona Pharma: Financial Health And COPD Market Impact 2024 Verona Pharma: Targeting The Large COPD Market Verona Pharma granted FDA review fo...
US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call today at 9:00 a.m. EDT / 1:00 p.m. GMT LONDON and RALEIG...
2023-10-20 17:24:19 ET Gainers: Day One Biopharmaceuticals ( DAWN ) +6% . ContextLogic ( WISH ) +5% . Vital Farms ( VITL ) +5% . Verona Pharma ( VRNA ) +4% . GoPro ( GPRO ) +3% . Losers: IGM Biosciences ( IG...
News, Short Squeeze, Breakout and More Instantly...
2024-07-05 11:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 07:00:04 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $36.00 for VRNA on 2024-06-27 06:09:00. The adjusted price target was set to $36.00. At the time of the announcement, VRNA was trading at $14.69. The overall price target consensus is...
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIG...